Efficacy and Safety of PF2998044 as First-line Treatment (Tx) of Patients (Pts) with Advanced (Adv) NSCLC Selected for Activating Mutation (Mu) of Epidermal Growth Factor Receptor (EGFR)
Refereed conference paper presented and published in conference proceedings


Full Text

Other information
All Author(s) ListMOK Shu Kam Tony, SPIGEL R D, PARK K, SOCINSKI A M, TUNG Y S, KIM W D, OU I Sh, ZHANG H, OCONNELL P J, JANNE P
Name of Conference35th ESMO Congress
Country/Region of ConferenceGreat Britain
Proceedings Title35th ESMO Congress
Detailed descriptionorganized by European Society for Medical Oncology,
Year2010
Month10
Place of PublicationUnited Kingdom
Pages2
LanguagesEnglish-United Kingdom
KeywordsEGFR; Advanced NSCLC

Last updated on 2018-23-01 at 18:13